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ABSTRACT
Objective: Versatile biological activities of nitrogen containing heterocycles in medicinal chemistry, mainly pyrimidine and pyridine ring based 
heterocyclic moieties are very important. Pharmaceutical important of pyrimidine and isoniazid moiety prompted us to synthesize isoniazid clubbed 
pyrimidine derivatives and evaluated for antimicrobial and antituberculosis activity.
Method: 2-(2-(3-bromo benzylidene)-1-isonicotinoyl hydrazinyl)-N-(4-(substituted phenyl)-6-(substituted aryl) pyrimidin-2-yl) acetamide 2(A-J) 
have been synthesized by condensation reaction of 2-chloro-N-[4-(substituted phenyl)-6-(substituted aryl) pyrimidin-2-yl] acetamide and N’-[(E)-
(3-bromophenyl) methylidene]pyridine-4-carbohydrazide. All newly synthesized compounds were screened for in vitro antibacterial activity against 
Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus pyogenes, antifungal against Candida albicans, Aspergillus niger, 
and Aspergillus clavatus, and antituberculosis activity against Mycobacterium tuberculosis H37RV.
Results: Majority of the compounds exhibited good antibacterial, antifungal, and antituberculosis activity. All titled compounds were characterized 
by spectral analyses (infrared spectroscopy, nuclear magnetic resonance spectroscopy, and mass spectroscopy).
Conclusion: 2-(2-(3-bromo benzylidene)-1-isonicotinoyl hydrazinyl)-N-(4-(substituted phenyl)-6-(substituted aryl) pyrimidin-2-yl) acetamide 2(A-J) 
showed good antimicrobial activity and comparatively good antituberculosis activity. Hence, all the compounds of this series considered for future 
investigation mainly in area of antibacterial, antifungal study.
Keywords: Pyrimidine, Pyridine, Isoniazid, Antimicrobial, Antituberculosis.
INTRODUCTION
Isoniazid (isonicotinic acid hydrazide) used as the first-line antibiotic for 
tuberculosis treatment since 1952. It is prodrug which is activated by 
Mycobacterium tuberculosis catalase-peroxidase (Kat G) is a bifunctional 
hemoprotein [1]. The primary target of isoniazid (INH) is the enoyl-ACP 
reductase enzyme (InhA) from M. tuberculosis. Isoniazid is a derivative 
of nicotinic acid, which possesses antibacterial, antioxidant, anti-
inflammatory, and anticarcinogenic activities and showed putative activity 
against osteoarthritis and granuloma annulare. Nicotinic acid (Niacin 
or vitamin B3) derivatives are also very important starting material to 
prepare bioactive moieties [2]. Likewise, pyrimidine also appeared as an 
important pharmacophore used as building blocks of numerous natural 
compounds and found in vitamins (thiamine, riboflavin, and folic acid), 
lipopolysaccharides, DNA, and RNA. The synthetic drugs such as HIV drugs, 
barbiturates, anticancer agents, antimicrobial, antiviral, antimalarial, 
and anti-inflammatory [3-9]. Structural modification of pyrimidine with 
different functional groups or other heterocycles may improve clinical 
outcomes [10-19]. Due to this importance of isoniazid (nicotinic acid 
derivatives) and pyrimidine nucleus, we thought to synthesize isoniazid 
clubbed pyrimidine derivatives and evaluated in vitro antibacterial 
activity against several kinds of bacteria, fungi, and M. tuberculosis H37Rv.
In this study, newly synthesized 2-(2-(3-bromo 
benzylidene) -1-isonicotinoyl hydrazinyl) -N-(4-(substituted 
phenyl) -6-(substituted aryl) pyrimidin-2-yl) acetamide 2 (A-J) were 
identified and characterized by spectral analysis (IR, nuclear magnetic 
resonance [NMR], and mass) and elemental analysis. Antibacterial 
studies were performed toward Escherichia coli, Pseudomonas 
aeruginosa, Staphylococcus aureus and Staphylococcus pyogenes, 
antifungal activities against Candida albicans, Aspergillus niger, and 
Aspergillus clavatus. The majority of the compounds were showed a 
high degree of evaluation toward Gram-positive and Gram-negative 
bacteria as compared to standard drug ampicillin. Antifungal activity 
of many moieties was comparatively high as compared with standard 
drug Griseofulvin. Where some of the newly synthesized compounds 
showed good antitubercular activity.
METHODS
The chemicals used in the synthesis were purchased from commercial 
sources were of analytical grade and were used without further 
purification. Laboratory Chemicals were supplied by Sigma-Aldrich and 
Fisher Scientific Ltd. Melting points were determined by the open tube 
capillary method and are uncorrected. The purity of the compounds 
was determined by thin layer chromatography (TLC) plates (silica gel G) 
using different eluent system. The IR spectra were obtained on Fourier 
transform infrared spectroscopy (FT-IR). Infrared spectrophotometer 
model RZX (Perkin Elmer) and Agilent resolution Pro FT-IR spectrometer 
using potassium bromide pellets; the frequencies are expressed in cm−1. 
The 1H-NMR and 13C-NMR spectra were recorded on a Bruker Advance 
II 400 spectrometer (100 MHz FT-NMR) using tetramethylsilane as 
the internal standard in deuterochloroform (CDCl3) and dimethyl 
sulfoxide (DMSO-d6) (chemical shifts in δ ppm). Mass spectra recorded 
WATERS Q-T of micro mass (electrospray ionization-MS). Column 
chromatography was performed on silica gel 60 (0.043-0.06 mm) Merck. 
Elemental analysis was performed on Carlo Erba1108 analyzer, and the 
result was varying within ±0.04% of the calculated values.
General method of synthesis
Synthesis of (2E)-1-(4-substituted phenyl)-3-(substituted phenyl)
prop-2-en-1-one derivatives (A)
α-β unsaturated ketone [20] compounds were prepared by reported 
method [21-24].
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i10.19302
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Synthesis of 4-(4-substituted phenyl)-6-(substituted phenyl)
pyrimidin-2-amine derivatives (B)
A synthesized compound (A) (10 mmol), guanidine nitrate (15 mmol) 
and were dissolved in ethanol (10 mL) and added sodium methoxide in 
methanol (25%, 20 mL) was refluxed for 6-8 hrs. The progress of the 
reaction was monitored by TLC using toluene:ethyl acetate (2.5:7.5), 
interval of every 30 minutes and after completion of the reaction, the 
mixture was cooled, diluted with water and filtered. The separated 
solid compound was washed with water, dried and recrystallized with 
ethanol to get (B).
Synthesis of 2-chloro-N-[4-(substituted phenyl)-6-(4-substituted 
phenyl)pyrimidin-2-yl] acetamide (C)
A synthesized compound (B) (10 mmol) dissolved in dichloromethane 
(15 mL) and dropwise addition of chloroacetyl chloride (15 mmol). 
Then added triethylamine (10 mmol). Reaction mass was stirred for 
3 hrs. The progress of the reaction was monitored by TLC using toluene: 
methanol:ethyl acetate (2:3:5), interval of every 30 minutes and after 
completion of the reaction, the mixture diluted with water and the 
organic layer was separated. The separated liquid compound was dried, 
washed water and recrystallized with ethanol to get (C).
Synthesis of N’-[(E)-(3-bromophenyl) methylidene]pyridine-4-
carbohydrazide (D)
This compound was prepared by reported method [25,26].
Synthesis of 2-(2-(3-Bromo benzylidene)-1-isonicotinoyl 
hydrazinyl)-N-(4-(substituted phenyl)-6-(substituted aryl) 
pyrimidin-2-yl) acetamide (E)
A synthesized compound (D) (10 mmol) was dissolved in 15 mL 
methanol, and 3.4 g of K2CO3 was added. The reaction mixture was 
refluxed on a water bath. A dropping funnel was fitted to the round 
bottom flask, and in the dropping funnel, a solution of synthesized 
compound (C) (10 mmol) in 20 mL methanol was taken. A slow 
addition of this solution was done. The reaction mixture was refluxed 
in water bath at 80°C for 4 hrs. The reaction was monitored by TLC 
using toluene:ethyl acetate (2:8). After completion of the reaction, the 
mixture was kept at room temperature. After filtration, it was washed 
with water and crystallized from ethanol to get (E). The crude solid was 
purified by column chromatography.
Biological evaluation
In vitro biological evaluation
Minimum inhibition concentration method for antimicrobial activity.
For nutrient medium Mueller–Hinton broth was used as to grow 
and dilute the drug suspension for the test. Size of inoculum for test 
strain was adjusted to 108 colony forming unit. DMSO was used for 
negative control and as diluents to get the desired concentration of 
drugs to test on standard bacterial strains. For primary and secondary 
screening serial dilutions were prepared. The control tube containing 
no antibiotic was immediately subcultured (before inoculation) by 
spreading a loopful evenly over a quarter of plate of medium suitable 
for the growth of the test organism and put for incubation at 37°C 
24 hrs. The minimum inhibitory concentration (MIC) of the control 
organism was read to check the accuracy of the drug concentrations. 
The standard drug used in this method was ampicillin, chloramphenicol, 
ciprofloxacin, griseofulvin, and nystatin. The lowest concentration 
inhibiting the growth of the organism was recorded as the MIC. 
The amount of growth of the control tube before incubation (which 
represents the original inoculum) was compared. The test included a 
second set of the same dilutions inoculated with an organism of known 
sensitivity. Each synthesized drug was diluted obtaining 1000 μg/mL 
concentration, as a stock solution. In primary screening 500, 250, and 
125 µg/mL concentrations of the synthesized drugs were taken. The 
active synthesized drugs found in this primary screening were further 
tested in a second set of dilution against all microorganisms. The drugs 
found active in primary screening were similarly diluted to obtain 
100, 50, 25, 12.5, 6.250, 3.125, and 1.5625 µg/mL concentrations. 
The highest dilution showing at least 99% inhibition is taken as MIC 
(Table 1) [27,28].
RESULTS
Synthetic route for title compounds given in Figs. 1 and 2. The 
pyrimidine ring system was prepared by 4-(4-substituted 
phenyl) -6-(substituted aryl) pyrimidine-2-amine. This compound 
was key intermediate required for the synthesis of title compounds. 
This compound further reacted with chloroacetyl chloride and given 
2-chloro-N-[4-(substituted phenyl)-6-(4- substituted aryl) pyrimidin-
2-yl] acetamide (A). To prepare final yield, compound (A) condensed 
with N’-[(E)-(3-bromophenyl)methylidene]pyridine-4-carbohydrazide 
in the presence of K2CO3, Which yielded (E)-2-(2-(3-Bromo 
benzylidene)-1-isonicotinoyl hydrazinyl)-N-(4-(substituted phenyl)-
6-(substituted aryl) pyrimidin-2-yl) acetamide (2A-J). Spectral studies 
of these compounds proved the structure of derivatives. IR absorption 
band of compound 2A, IR (KBr) cm−1: 3432.80 (N-H), 3190.58, 3051.74 
for aromatic C-H, 1652.88 (-CONH), 1356.10, 1252.29, 1218.37, 
1171.87, 1140.44 (C-N), and 573.76 (C-Br). 1H NMR spectrum of the 
compound recorded in CDCl3, singlet of 1H at 8.62 for CH of pyrimidine 
ring, 17H of aromatic CH appeared at 7.31-8.77, singlet of 1H at 5.33 for 
NH, disappeared on D2O exchange and singlet of 2H for CH2 recorded 
at 3.85. 13C NMR of the final compound showed at 168.05, 167.78 for 
C=O, 164.38 for C=N of pyrimidine, 155.3-113.43 for aromatic carbon, 
and 54.41 for CH2 confirming the formation of a final compound. 
Fig. 1: General synthesis of 2-chloro-N-[4-(substituted 
phenyl)-6-(4- substituted phenyl) pyrimidin-2-yl] acetamide 
derivatives. Reagents and conditions: (a) CH3OH, NaOH, stirred at 
room temperature 2 hrs, (b) guanidine nitrate, CH3ONa, CH3OH, 
reflux 8 hrs (C) dichloromethane, chloroacetyl chloride, and 
triethylamine
Fig. 2: General synthesis of 2-(2-(3-bromo benzylidene)-
1-isonicotinoyl hydrazinyl)-N-(4-(substituted phenyl)-6-
(substituted aryl) pyrimidin-2-yl) acetamide derivatives. 
Reagents and conditions: (a) CH3OH, CH3COOH, reflux 2 hrs 
(b) CH3OH, K2CO3 reflux 4 hrs
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Mass spectra of the synthesized compounds showed M+/M+1 peak, 
confirmed their molecular formula. The analytical data of synthesized 
compounds are as follows.
(E)-2-(2-(3-bromobenzylidene)-1-isonicotinoylhydrazinyl)-N-(4-
(4-fluorophenyl)-6-(pyridin-2-yl)pyrimidin-2-yl)acetamide 2A
IR: 3432.80 (N-H), 3190.58, 3051.74, (C-H aromatic), 1652.88 (-CONH), 
1544.72 (N-H bending), 1429.32, 1476.17 (C=C aromatic), 1356.10, 
1252.29, 1218.37, 1171.87, 1140.44 (C-N), 1063.01 (C-F) 573.76 
(mono substituted Br). 1H-NMR (CDCl3, 400 MHz): 8.62 (s, 1H, CH of 
pyrimidine ring); 7.31-8.77 (m, 16H, Ar-H); 8.39 (s, 1H, CH); 5.33 (s, 1H, 
CONH); 3.85 (s, 2H, CH2). 13C-NMR (CDCl3, 400 MHz): 168.51, 165.62 
(C=O); 162.91 (C=N, C1, pyrimidine); 155.30; 101.30-149.71; 146.91 
(aromatic ring), 55.40 (CH2). MS (m/z): 609.09 ([M + H] +), 611.09 
[M++2], elemental analysis calculated for C30 H21 Br FN7 O2: C 59.03, H 
3.47, N 16.06; found: C 59.04, H 3.45, N 16.04.
(E)-2-(2-(3-bromobenzylidene)-1-isonicotinoylhydrazinyl)-N-(4-
(4-fluorophenyl)-6-(pyridin-3-yl)pyrimidin-2-yl)acetamide 2B
IR: 3430.70 (N-H), 3190.58, 3041.44, (C-H aromatic), 1657.18 (-CONH), 
1544.72 (N-H bending), 1429.32, 1476.17 (C=C, aromatic), 1356.10, 
1252.29, 1218.37, and 1170.87 (C-N), 1061.31 (C-F) 577.66 (mono 
substituted Br). 1H-NMR (CDCl3, 400 MHz): 8.66 (s, 1H, CH of pyrimidine 
ring); 6.68-8.78 (m, 16H, Ar-H); 8.45 (s, 1H, CH); 5.63 (s, 1H, CONH); 
Table 1: Physical data of the compounds (2A-J)
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3.85 (s, 2H, CH2). 13C-NMR (CDCl3, 100 MHz): 166.24, 165.74 (C=O); 
160.20 (Pyrimidine); 149.97-101.75 (aromatic ring); 55.04 (CH2). MS 
(m/z): 609.09 ([M + H] +), 611.09 [M++2], elemental analysis calculated 




IR: 3423.46, 3351.91 (N-H), 3125.58, 3057.84, (C-H aromatic), 1657.98 
(-CONH), 1549.72 (N-H bending), 1429.32, 1476.87 (C=C, aromatic), 
1356.10, 1252.29, 1218.37, and 1180.87 (C-N), 1067.31 (C-F) 567.86 
(mono substituted Br). 1H-NMR (CDCl3, 400 MHz): 8.61 (s, 1H, CH of 
pyrimidine ring); 7.31-8.77 (m, 16H, Ar-H); 8.39 (s, 1H, CH); 5.33 (s, 1H, 
CONH); 3.85 (s, 2H, CH2). 13C-NMR (CDCl3, 100 MHz): 168.51, 162.91 
(C=O); 160.60 (pyrimidine); 106.20-148.82 (aromatic ring); 55.41 
(CH2). MS (m/z): 609.09 ([M + H] +), 611.09 [M++2], elemental analysis 
calculated for C30 H21 Br FN7 O2: C 59.03, H 3.47, N 16.06; found: C 59.15, 




IR: 3472.56, 3303.45 (N-H), 3056.70, (C-H aromatic), 1651.75 (-CONH), 
1591.78 (N-H bending), 1428.37, 1472.37 (C=C, aromatic), 1308.26, 
1234.07, 1165.55, and 1140.44 (C-N), 1024.41 (C-F) 573.76 (mono 
substituted Br). 1H-NMR (CDCl3, 400 MHz): 8.61 (s, 1H, CH of pyrimidine 
ring); 7.31-8.77 (m, 16H, Ar-H); 8.39 (s, 1H, CH); 5.35 (s, 1H, CONH); 
3.85 (s, 2H, CH2). 13C-NMR (CDCl3, 100 MHz):168.54, 162.92 (C=O); 
140.81-107.08; 55.41 (CH2). MS (m/z): 688.09 ([M + H] +), 690.09 
[M++2], elemental analysis calculated for C31 H21 Br2 FN6 O2: C 54.09, H 
3.08, N 12.21; found: C 54.11, H 3.09, N 12.23.
(E)-2-(2-(3-bromobenzylidene)-1-isonicotinoylhydrazinyl)-N-(4-
(3-chlorophenyl)-6-(4-fluorophenyl)pyrimidin-2-yl)acetamide 2E
IR: 3341.42 (N-H), 3060.39, 3033.38 (C-H aromatic), 1673.22 (-CONH), 
1553.21 (N-H bending), 1433.36, 1472.37 (C=C, aromatic), 1267.26, 
1218.37, 1183.49, and 1140.64 (C-N), 1024.41 (C-F), 688.12 (C-Cl), 
573.76 (mono substituted Br). 1H-NMR (CDCl3, 400 MHz): 8.61 (s, 1H, 
CH of pyrimidine ring); 7.31-8.77 (m, 17H, Ar-H); 8.38 (s, 1H, CH); 5.35 
(s, 1H, CONH); 3.85 (s, 2H, CH2). 13C-NMR (CDCl3, 100 MHz): 168.51, 
162.69 (C=O); 146.95-107.08 (aromatic ring); 55.41 (CH2). MS (m/z): 
642.90 ([M + H] +), 643.88 [M++1], 644.09 [M++2], elemental analysis 
calculated for C31 H21 Br Cl FN6 O2: C 57.83, H 3.29, N 13.05; found: 
C 57.81, H 3.33, N 13.03.
(E)-2-(2-(3-bromobenzylidene)-1-isonicotinoylhydrazinyl)-N-(4-
(pyridin-2-yl)-6-(p-tolyl) pyrimidin-2-yl)acetamide 2F
IR: 3352.46 (N-H), 3056.39, 3022.38 (C-H aromatic), 2941.41, 2932.4 
(C-H), 1671.22 (-CONH), 1541.21 (N-H bending), 1413.36, 1423.38 
(C=C, aromatic), 1256.26, 1234.37, 1123.49 (C-N), 567.76 (mono 
substituted Br). 1H-NMR (CDCl3, 400 MHz): 8.64 (s, 1H, CH of pyrimidine 
ring), 7.42-8.77 (m, 16H, Ar-H); 8.39 (s, 1H, CH); 5.34 (s, 1H, CONH); 
3.85 (s, 2H, CH2); 2.34 (s, 3H, CH3). 13C-NMR (CDCl3, 100 MHz):168.35, 
165.46 (C=O); 162.76 (pyrimidine); 155.03; 149.71-101.39; 55.43 
(CH2), 21.34 (CH3). MS (m/z): 605.03 ([M + H] +), 606.13[M++1], 607.12 
[M++2], elemental analysis calculated for C31 H24 BrN7 O2: C 61.39, H 
3.99, N 16.17; found: C 61.34, H 3.97 N 16.11.
(E)-2-(2-(3-bromobenzylidene)-1-isonicotinoylhydrazinyl)-N-(4-
(pyridin-3-yl)-6-(p-tolyl) pyrimidin-2-yl)acetamide 2G
IR: 3431.13, 3331.42 (N-H), 3032.39, (C-H aromatic), 2932.50 (C-H), 
1671.21 (-CONH), 1539.21(N-H bend), 1412.46, 1441.37, 1461.37 
(C=C, aromatic), 1353.33, 1274.26, 1218.37, 1183.49, 1140.44 (C-N), 
573.76 (mono substituted Br). 1H-NMR (CDCl3, 400 MHz): 8.57 (s, 1H, 
CH of pyrimidine ring), 7.12-9.25 (m, 16H, Ar-H); 8.36 (s, 1H, CH); 5.23 
(s, 1H, CONH), 3.85 (s, 2H, CH2); 2.34 (s, 3H, CH3). 13C-NMR (CDCl3, 100 
MHz): 165.18; 163.93 (C=O); 149.99-123.23; 55.34 (CH2), 21.14 (CH3). 
MS (m/z): 605.13 ([M + H] +), 606.12[M++1], 607.13 [M++2], elemental 
analysis calculated for C31 H24 BrN7 O2: C 61.39, H 3.99, N 16.17; found: 
C 61.40, H 3.98 N 16.19.
(E)-2-(2-(3-bromobenzylidene)-1-isonicotinoylhydrazinyl)-N-(4-
(pyridin-4-yl)-6-(p-tolyl) pyrimidin-2-yl)acetamide 2H
IR: 3423.86 (N-H), 3032.19, (C-H aromatic), 1678.21 (-CONH), 
1532.21(N-H bend), 1412.46, 1451.37, (C=C, aromatic), 1353.33, 
1274.26, 1218.37, 1176.23, 1148.21 (C-N), 571.76 (mono substituted 
Br). 1H-NMR (CDCl3, 400 MHz): 8.62 (s, 1H, CH of pyrimidine ring), 
7.59-8.77 (m, 16H, Ar-H); 8.39 (s, 1H, CH); 5.31 (s, 1H, CONH); 3.85 (s, 
2H, CH2); 2.34 (s, 3H, CH3). 13C-NMR (CDCl3, 100 MHz): 168.25, 165.66; 
162.76 (C=O); 157.73 (Pyrimidine); 149.71-106.23 (aromatic ring); 
55.43 (CH2), 21.33 (CH3). MS (m/z): 605.13 ([M + H] +), 606.11[M++1], 
607.12 [M++2], elemental analysis calculated for C31 H24 BrN7 O2: C 61.39, 
H 3.99, N 16.17; found: C 61.41, H 3.97 N 16.18.
(E)-2-(2-(3-bromobenzylidene)-1-isonicotinoylhydrazinyl)-N-(4-
(3-bromophenyl)-6-(p-tolyl)pyrimidin-2-yl)acetamide 2I
IR: 3472.56, 3303.45 (N-H), 3199.37, 3060.39, 3032.38 (C-H aromatic), 
2951.44, 2922.4 (C-H), 1683.22 (-CONH), 1546.21 (N-H bend), 1412.36, 
1428.37, 1472.37 (C=C, aromatic), 1353.33, 1274.26, 1218.37, 1183.49, 
1140.44, 1189.57 (C-N), 573.76 (mono substituted Br). 1H-NMR 
(CDCl3, 400 MHz): 7.42-8.77 (m, 17H, Ar-H); 8.39 (s, 1H, CH); 5.34 (s, 
1H, CONH); 3.85 (s, 2H, CH2); 2.34 (s, 3H, CH3). 13C-NMR (CDCl3, 100 
MHz): 168.55, 165.76 (C=O); 160.26, 156.03 (pyrimidine); 149.71-
107.09 (aromatic ring); 55.43 (CH2), 21.53 (CH3). MS (m/z): 684.03([M 
+ H] +), 686.03[M++2], elemental analysis calculated for C32 H24 Br2 N6 O2: 
C 56.16, H 3.53, N 12.28; found: C 56.24, H 3.55, N 12.24.
(E)-2-(2-(3-bromobenzylidene)-1-isonicotinoylhydrazinyl)-N-(4-
(3-chlorophenyl)-6-(p-tolyl) pyrimidin-2-yl)acetamide 2J
IR: 3472.56, 3303.45 (N-H), 3199.37, 3060.39, 3032.38 (C-H aromatic), 
2951.44, 2922.4 (C-H), 1679.22 (-CONH), 1534.21 (N-H bend), 1412.36, 
1428.34, 1471.37 (C=C, aromatic), 1351.33, 1264.26, 1218.37, 1183.49, 
1140.44 (C-N), 834.23 (C-Cl) 581.76 (mono substituted Br). 1H-NMR 
(CDCl3, 400 MHz): 7.15-8.77 (m, 17H, Ar-H); 8.39 (s, 1H, CH); 5.34 (s, 1H, 
CONH); 3.85 (s, 2H, CH2); 2.34 (s, 3H, CH3). 13C-NMR (CDCl3, 100 MHz): 
168.89, 165.67 (C=O); 160.61, 156.03 (pyrimidine); 149.71-107.80 
(aromatic ring); 55.43 (CH2), 21.3 (CH3). MS (m/z): 638.08 ([M + H] +), 
639.08 [M++1], 640.03, elemental analysis calculated for C32 H24 BrClN6 
O2: C 60.06, H 3.78, N 13.13; found: C 60.04, H 3.75, N 13.10.
Table 2: In vitro antibacterial activity (MIC, µg/mL) of the 
synthesized compounds
Code number MIC µg/mL
E. coli P. aeruginosa S. aureus S. pyogenes
2A 200 100 250 100
2B 250 200 250 125
2C 200 100 500 200
2D 100 125 500 250
2E 250 200 250 250
2F 250 500 500 200
2G 500 250 250 125
2H 100 125 200 125
2I 500 100 125 200
2J 125 250 200 125
Ampicillin 100 100 250 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 25 25 50 50
MIC: Minimal inhibitory concentration, E. coli: Escherichia coli (MTCC 
no. 442), P. aeruginosa: Pseudomonas aeruginosa (MTCC no. 441), 
S. aureus: Staphylococcus aureus (MTCC no. 96), S. pyogenes: Staphylococcus 
pyogenes (MTCC no. 443), MTCC: Microbial type culture collection
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In vitro antimicrobial and antituberculosis activity
All the newly synthesized compounds were screened for their 
antimicrobial activity. This activity was determined by the broth micro 
dilution method according to the National Committee for Clinical 
Laboratory Standards [29,30]. For antibacterial activity, we used 
S. aureus microbial type culture collection (MTCC 96) and S. pyogenes 
(MTCC 443) as Gram-positive, E. coli (MTCC 442) and P. aeruginosa 
(MTCC 441) as Gram-negative strains using ampicillin, chloramphenicol, 
and ciprofloxacin as a standard antibacterial drug. Antifungal activity 
was screened for three different fungal spices C. albicans (MTCC 227), 
A. niger (MTCC 282), and A. clavatus (MTCC 1323). Griseofulvin and 
nystatin used as a standard antifungal drug. The strains were procured 
from Institute of Microbial Technology, Chandigarh.
DISCUSSION
Pyrimidine derivatives have been very well known in medicinal 
chemistry for their therapeutic applications. The presence of a 
pyrimidine base in thymine, cytosine and uracil, which are the essential 
binding blocks of nucleic acids, DNA and RNA is one possible reason 
for their activity. The literature indicated that compounds having 
pyrimidine nucleus possess a broad range of biological activities. Like 
5-fluorouracil as anticancer; idoxuridine and trifluridine as antiviral; 
zidovudine and stavudine as anti-HIV, trimethoprim, sulfamethazine, 
and sulfadiazine as antibacterial; sulfadoxine as antimalarial and 
antibacterial; minoxidil and prazosin as antihypertensive; barbiturates, 
e.g., phenobarbitone as sedative, hypnotics and anticonvulsant; 
propylthiouracil as antithyroid; thonzylamine as H1-antihistamine; 
toxoflavin and fervenulin as antibiotics. In this study, pyrimidine 
clubbed Schiff base of isoniazid have been taken for dual evaluations 
antimicrobial as well as antituberculosis. Isoniazid itself used as first-
line antituberculosis drug. When the Schiff of isoniazid clubbed with 
pyrimidine moiety the resulted compounds revealed good activities. 
Compounds 2A-E with fluorine group and 2G-J with a methyl group 
showed good antibacterial activity. Whereas fluorine group containing 
compounds 2A, 2D, and 2E was active toward C. albicans. Only one 
compound 2J showed good potential toward M. tuberculosis H37RV. 
All the compounds of this series with fluorine and the methyl group 
showed good potential as an antimicrobial agent and antituberculosis 
also which open door for future investigation. The results of all 
compounds against antibacterial activity were displayed in Table 2. 
Antifungal and antituberculosis activity results of the all compounds 
were displayed in Table 3. All synthesized compounds conducted at 
250 µg/mL, 500 µg/mL, and 1000 µg/mL for antituberculosis activity.
CONCLUSION
Most of the synthesized compounds showed good antibacterial 
activity against Gram-positive as well as Gram-negative bacteria. 
Compounds 2D and 2H were equally active against E. coli. Compound 
2A, 2C, and 2I showed very good activity toward P. aeruginosa. 2A, 2B, 
2E, 2G, 2H, 2I, and 2J showed excellent activity toward S. aureus. Only 
2A showed good activity against S. pyogenes as compared to standard 
drug ampicillin. Antifungal activity of compound 2A, 2D, and 2E equal 
against C. albicans compared with standard drug Griseofulvin. 
Other compounds were moderately sensitive toward A. niger and 
A. clavatus. All the compounds were active against Mycobacterium 
tuberculosis H37RV, but mainly more active compounds were 2A, 2B, 
2C, 2D, 2G, 2H, and 2J. Among of them, compound 2J was highly active 
moiety as compared to another compound. The final conclusion of 
this series is that this class of molecules certainly holds great promise 
toward the pursuit to discover the novel class of antimicrobial and 
antituberculosis agents.
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